An Open Label Study of the Effect of First Line Treatment With Bevacizumab in Combination With Capecitabine and Oxaliplatin on Progression-free Survival in Patients With Metastatic Cancer of the Colon and Rectum
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Colorectal Cancer
Both
Colorectal Cancer
Trial Information
An Open Label Study of the Effect of First Line Treatment With Bevacizumab in Combination With Capecitabine and Oxaliplatin on Progression-free Survival in Patients With Metastatic Cancer of the Colon and Rectum
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Metastatic colorectal cancer
- Treatment in accordance with current Summary of Product Characteristics and local
guidelines
Exclusion Criteria:
- Contraindications according to current Summary of Product Characteristics and local
guidelines
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Progression-free survival (tumour assessments according to RECIST criteria)
Outcome Time Frame:
approximately 30 months
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Slovakia: State Institute for the Control of Drugs
Study ID:
ML25523
NCT ID:
NCT01399190
Start Date:
July 2011
Completion Date:
December 2013
Related Keywords:
- Colorectal Cancer
- Colorectal Neoplasms
Name | Location |
|---|
